Progression while receiving preoperative chemotherapy should not be an absolute contraindication to liver resection for colorectal metastases

Annals of Surgical Oncology

Volumn 19, Issue 9, 2012, Pages 2786-2796

  Viganó, Luca ^a   Capussotti, Lorenzo ^a   Barroso, Eduardo ^b   Nuzzo, Gennaro ^c   Laurent, Christophe ^d   Ijzermans, Jan N M ^e   Gigot, Jean François ^f   Figueras, Joan ^g   Gruenberger, Thomas ^h   Mirza, Darius F ⁱ   Elias, Dominique ^j   Poston, Graeme ^k   Letoublon, Christian ^l   Isoniemi, Helena ^m   Herrera, Javier ⁿ   Sousa, Francisco Castro ^o   Pardo, Fernando ^p   Lucidi, Valerio ^q   Popescu, Irinel ^r   Adam, René ^s  

^a MAURIZIANO HOSPITAL   (Italy)

^b HOSPITAL CURRY CABRAL   (Portugal)

^c CATHOLIC UNIVERSITY   (Italy)

^d HÔPITAL SAINT ANDRÉ   (France)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^g Hospital Universari Josep Trueta   (Spain)

^h MEDICAL UNIVERSITY OF VIENNA   (Austria)

ⁱ QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^j INSTITUT GUSTAVE ROUSSY   (France)

^k UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

^l GRENOBLE UNIVERSITY HOSPITAL   (France)

^m HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

ⁿ Universidad Pública de Navarra   (Spain)

^o CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^p UNIVERSITY CLINIC OF NAVARRA   (Spain)

^q ERASME HOSPITAL   (Belgium)

^r FUNDENI CLINICAL INSTITUTE   (Romania)

^s HÔPITAL PAUL BROUSSE   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARCINOEMBRYONIC ANTIGEN; CETUXIMAB; FLUOROURACIL; IRINOTECAN; OXALIPLATIN;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PROGNOSIS; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; COLORECTAL CANCER; FEMALE; HUMAN; LIVER METASTASIS; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PREOPERATIVE TREATMENT; SURVIVAL PREDICTION; TREATMENT CONTRAINDICATION; TUMOR VOLUME;

AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOEMBRYONIC ANTIGEN; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HEPATECTOMY; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MULTIVARIATE ANALYSIS; NEOADJUVANT THERAPY; ORGANOPLATINUM COMPOUNDS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TUMOR BURDEN;

EID: 84867388810     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-012-2382-7     Document Type: Article

References (22)

1. Bismuth H, Adam R, Lévi F, et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg. 1996;224:509-20.
2. Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg. 2004;240:644-57.
3. Capussotti L, Muratore A, Mulas MM, Massucco P, Aglietta M. Neoadjuvant chemotherapy and resection for initially irresectable colorectal liver metastases. Br J Surg. 2006;93:1001-6.
4. Adam R, Pascal G, Castaing D, et al. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg. 2004;240:1052-61.
5. Allen PJ, Kemeny N, Jarnagin W, DeMatteo R, Blumgart L, Fong Y. Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases. J Gastrointest Surg. 2003;7:109-15.
6. Tanaka K, Adam R, Shimada H, Azoulay D, Lévi F, Bismuth H. Role of neoadjuvant chemotherapy in the treatment of multiple colorectal metastases to the liver. Br J Surg. 2003;90:963-9.
7. Capussotti L, Vigano' L, Ferrero A, Lo Tesoriere R, Ribero D, Polastri R. Timing of resection of liver metastases synchronous to colorectal tumor: proposal of prognosis based decisional model. Ann Surg Oncol. 2007;14:1143-50.
8. Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet. 2008;371(9617):1007-16.
9. Rubbia-Brandt L, Giostra E, Brezault C, et al. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neoadjuvant chemotherapy followed by liver surgery. Ann Oncol. 2007;18:299-304.
10. Adam R, Wicherts DA, de Haas RJ, et al. Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: myth or reality? J Clin Oncol. 2008;26:1635-41.
11. Vauthey JN, Pawlik TM, Ribero D, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol. 2006;24:2065-72.
12. Benoist S, Brouquet A, Penna C, et al. Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol. 2006;24:3939-45.
13. Gruenberger B, Tamandl D, Schueller J, et al. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol. 2008;26:1830-5.
14. Kornprat P, Jarnagin WR, Gonen M, et al. Outcome after hepatectomy for multiple (four or more) colorectal metastases in the era of effective chemotherapy. Ann Surg Oncol. 2007;14:1151-60.
15. Neumann UP, Thelen A, Röcken C, et al. Nonresponse to preoperative chemotherapy does not preclude long-term survival after liver resection in patients with colorectal liver metastases. Surgery. 2009;146:52-9.
16. World Health Organization. Handbook for reporting results of cancer treatment. WHO offset publication no. 48. Geneva: World Health Organization, 1979.
17. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-16.
18. Cox DR. Regression models and life tables. J R Stat Soc. 1972; B34:187-202.
19. Breslow NE. Covariance analysis of censored survival data. Biometrics. 1974;30:89-99.
20. Gallagher DJ, Zheng J, Capanu M, et al. Response to neoadjuvant chemotherapy does not predict overall survival for patients with synchronous colorectal hepatic metastases. Ann Surg Oncol. 2009;16:1844-51.
21. Adam R, Bhangui P, Poston G, et al. Is perioperative chemotherapy useful for solitary, metachronous, colorectal liver metastases? Ann Surg. 2010;252:774-87.
22. de Jong MC, Pulitano C, Ribero D, et al. Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients. Ann Surg. 2009;250:440-8.